Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Baxalta
- 20 May 2013 Planned end date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 20 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Jan 2013 Baxter continues enrolment in this confirmatory phase III trial, according to a company issued media release.